Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Chemomab Therapeutics reported their second quarter 2026 financial results showing steady R&D and administrative expenses with a net loss of $2.2 million. The company is progressing a planned merger with Scipher Medicine, valuing the combined entity at $150 million plus a concurrent $30 million financing. The merger would focus resources on advanci…